Bambusa Therapeutics presents positive Phase 1 data for bispecific antibody BBT002 at EAACI 2026
June 16, 2026 | 09:37
Bambusa Therapeutics has presented positive preliminary multiple ascending dose Phase 1 data for BBT002, a next-generation long-acting bispecific antibody targeting IL-4Rα and IL-5, at the European Academy of Allergy & Clinical Immunology Annual Congress 2026.
Mobile Version